Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven…
Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the seven…
For the estimated 2 million diagnosed patients in the United States who suffer from rheumatoid arthritis (RA), there are multiple prescription therapies that are available for treating the…
Outpatient parenteral antimicrobial therapy (OPAT) is a convenient mechanism for treating patients with infections that require intravenous (IV) antibiotic drugs but are clinically stable and do…
Patients surgically treated for orthopedic indications have a unique set of characteristics when compared with other surgical patients; critically, surgical treatment for these patients is often…
Improving survival among those with advanced cancer along with a high rate of cancer-related pain in this patient population will lead to steady growth in the prevalence of cancer pain in the…
With a series of recent advancements in pharmaceutical market access, Japan is transforming into a market where companies with innovative products can benefit from more opportunities. In addition,…
This third-time report focuses on the management of diabetic nephropathy (DN) in the United States. The U.S. market for DN drugs is poised to expand owing to the growing size of the DN patient…
The United States accounts for the single largest proportion of the global medical device market, representing approximately 40% of the estimated $400 billion (USD) global market in 2014. Its large…
Diabetic macular edema (DME) is a progressive ophthalmological comorbidity of diabetes that can threaten vision. In DME, fluid and lipids leak from abnormal, weak retinal blood vessels, causing…
Myelodysplastic syndromes (MDS) consists of a group of hematological stem cell disorders that are heterogeneous in cause and manifestations but share the common features of aberrant hematopoiesis…
Last Updated 2 November 2015 Fueled by multiple label expansions of premium-priced agents and the launch of four novel therapies, the NHL market will experience significant growth over the ten-year…
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…
Market Access Opportunities for Novel Therapies Targeting Multi-Drug-Resistant Pathogens Hospital-treated Gram-negative infections (GNIs) are becoming increasingly difficult to treat given rising…
